The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone

References

• American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Disorders5th edWashington, DCAmerican Psychiatric Association2013
   Google Scholar
• PattenSBWilliamsJVLavoratoDHWhy is major depression prevalence not changing?J Affect Disord2016190939726485311
   PubMed Web of Science ®Google Scholar
• PattenSBWilliamsJVLavoratoDHDescriptive epidemiology of major depressive disorder in Canada in 2012Can J Psychiatry2015601233025886546
   PubMed Web of Science ®Google Scholar
• PattenSBWangJLWilliamsJVDescriptive epidemiology of major depression in CanadaCan J Psychiatry2006512849016989107
   PubMed Web of Science ®Google Scholar
• SteensmaCLoukineLOrpanaHDescribing the population health burden of depression: health-adjusted life expectancy by depression status in CanadaHealth Promot Chronic Dis Prev Can2016361020521327768557
   PubMed Web of Science ®Google Scholar
• BlierPBrileyMThe noradrenergic symptom cluster: clinical expression and neuropharmacologyNeuropsychiatr Dis Treat20117Suppl 1152021750624
   PubMedGoogle Scholar
• NuttDJRelationship of neurotransmitters to the symptoms of major depressive disorderJ Clin Psychiatry200869Suppl E147
   PubMed Web of Science ®Google Scholar
• FriedEINesseRMDepression sum-scores don’t add up: why analyzing specific depression symptoms is essentialBMC Med2015137225879936
   PubMed Web of Science ®Google Scholar
• LamRWMcIntoshDWangJCanadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical guidelines for the management of adults with major depressive disorder: section 1. Disease burden and principles of careCan J Psychiatry201661951052327486151
   PubMed Web of Science ®Google Scholar
• KennedySHLamRWMcIntyreRSCanadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatmentsCan J Psychiatry201661954056027486148
   PubMed Web of Science ®Google Scholar
• Trintellix (vortioxetine). US prescribing informationDeerfield (IL)Takeda Pharmaceuticals America, Inc2016
   Google Scholar
• KatonaCLKatonaCPNew generation multi-modal antidepressants: focus on vortioxetine for major depressive disorderNeuropsychiatr Dis Treat20141034935424570588
   PubMed Web of Science ®Google Scholar
• BaldwinDSChronesLFloreaIThe safety and tolerability of vortioxetine: analysis of data from randomized placebo-controlled trials and open-label extension studiesJ Psychopharmacol201630324225226864543
   PubMed Web of Science ®Google Scholar
• SanchezCAsinKEArtigasFVortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical dataPharmacol Ther2015145435725016186
   PubMed Web of Science ®Google Scholar
• AlvarezEPerezVDragheimMA double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorderInt J Neuropsychopharmacol201215558960021767441
   PubMed Web of Science ®Google Scholar
• HenigsbergNMahableshwarkarARJacobsenPA randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21,004 in adults with major depressive disorderJ Clin Psychiatry201273795395922901346
   PubMed Web of Science ®Google Scholar
• BoulengerJPLoftHOlsenCKEfficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorderInt Clin Psychopharmacol201429313814924257717
   PubMed Web of Science ®Google Scholar
• MahableshwarkarARJacobsenPLChenYA randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDDPsychopharmacology (Berl)2015232122061207025575488
   PubMed Web of Science ®Google Scholar
• JacobsenPLMahableshwarkarARSerenkoMA randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorderJ Clin Psychiatry201576557558226035185
   PubMed Web of Science ®Google Scholar
• KatonaCHansenTOlsenCKA randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21,004 in elderly patients with major depressive disorderInt Clin Psychopharmacol201227421522322572889
   PubMed Web of Science ®Google Scholar
• ThaseMEMahableshwarkarARDragheimMA meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adultsEur Neuropsychopharmacol201626697999327139079
   PubMed Web of Science ®Google Scholar
• McIntyreRSFloreaITonnoirBLoftHLamRWChristensenMCEfficacy of vortioxetine on cognitive functioning in working patients with major depressive disorderJ Clin Psychiatry201778111512127780334
   PubMed Web of Science ®Google Scholar
• McIntyreRSHarrisonJLoftHJacobsonWOlsenCKThe effects of vortioxetine on cognitive function in patients with major depressive disorder: a meta-analysis of three randomized controlled trialsInt J Neuropsychopharmacol Epub2016824
   PubMed Web of Science ®Google Scholar
• RosenblatJDKakarRMcIntyreRSThe cognitive effects of antidepressants in major depressive disorder: a systematic review and meta-analysis of randomized clinical trialsInt J Neuropsychopharmacol2015192113
   Web of Science ®Google Scholar
• BoulengerJPLoftHFloreaIA randomized clinical study of Lu AA21,004 in the prevention of relapse in patients with major depressive disorderJ Psychopharmacol201226111408141622495621
   PubMed Web of Science ®Google Scholar
• Trintellix (vortioxetine). Product monographSt-Laurent, Quebec, CanadaLundbeck Canada Inc2016
   Google Scholar
• JacobsenPLMahableshwarkarARChenYEffect of vortioxetine versus. escitalopram on sexual functioning in adults with well-treated major depressive disorder experiencing SSRI-Induced sexual dysfunctionJ Sex Med201512102036204826331383
   PubMed Web of Science ®Google Scholar
• Fetzima (levomilnacipran extended release). US prescribing informationIrvine, CAAllergan USA, Inc2017
   Google Scholar
• AuclairALMartelJCAssieMBLevomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxietyNeuropharmacology20137033834723499664
   PubMed Web of Science ®Google Scholar
• AsnisGMBoseAGommollCPEfficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled studyJ Clin Psychiatry201374324224823561229
   PubMed Web of Science ®Google Scholar
• BakishDBoseAGommollCLevomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled studyJ Psychiatry Neurosci2014391404924144196
   PubMed Web of Science ®Google Scholar
• SambunarisABoseAGommollCPA phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorderJ Clin Psychopharmacol2014341475624172209
   PubMed Web of Science ®Google Scholar
• DurgamSChenCMiglioreRRelapse prevention with levomilnacipran ER in adults with major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study [abstract]American Psychiatric Association Annual MeetingMay 20–24; 2017San Diego, CA
   Google Scholar
• ThaseMEGommollCChenCEffects of levomilnacipran extended-release on motivation/energy and functioning in adults with major depressive disorderInt Clin Psychopharmacol201631633234027455513
   PubMed Web of Science ®Google Scholar
• BrunoAMorabitoPSpinaEThe role of levomilnacipran in the management of major depressive disorder: a comprehensive reviewCurr Neuropharmacol201614219119926572745
   PubMed Web of Science ®Google Scholar
• McIntyreRSGommollCChenCThe efficacy of levomilnacipran ER across symptoms of major depressive disorder: a post hoc analysis of 5 randomized, double-blind, placebo-controlled trialsCNS Spectr201621538539227292817
   PubMed Web of Science ®Google Scholar
• MagoRForeroGGreenbergWMSafety and tolerability of levomilnacipran ER in major depressive disorder: results from an open-label, 48-week extension studyClin Drug Investig20133310761771
   PubMed Web of Science ®Google Scholar
• Viibryd (vilazodone). US prescribing informationIrvine, CAAllergan USA, Inc2017
   Google Scholar
• SinghMSchwartzTLClinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical useNeuropsychiatr Dis Treat2012812313022536068
   PubMed Web of Science ®Google Scholar
• RickelsKAthanasiouMRobinsonDSEvidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trialJ Clin Psychiatry200970332633319284933
   PubMed Web of Science ®Google Scholar
• KhanACutlerAJKajdaszDKA randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorderJ Clin Psychiatry201172444144721527122
   PubMed Web of Science ®Google Scholar
• MathewsMGommollCChenDEfficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trialInt Clin Psychopharmacol2015302677425500685
   PubMed Web of Science ®Google Scholar
• CroftHAPomaraNGommollCEfficacy and safety of vilazodone in major depressive disorder: a randomized, double-blind, placebo-controlled trialJ Clin Psychiatry20147511e1291e129825470094
   PubMed Web of Science ®Google Scholar
• KhanASambunarisAEdwardsJVilazodone in the treatment of major depressive disorder: efficacy across symptoms and severity of depressionInt Clin Psychopharmacol2014292869224247740
   PubMed Web of Science ®Google Scholar
• ThaseMEChenDEdwardsJEfficacy of vilazodone on anxiety symptoms in patients with major depressive disorderInt Clin Psychopharmacol201429635135624978955
   PubMed Web of Science ®Google Scholar
• GommollCDurgamSMathewsMA double-blind, randomized, placebo-controlled, fixed-dose phase III study of vilazodone in patients with generalized anxiety disorderDepress Anxiety201532645145925891440
   PubMed Web of Science ®Google Scholar
• GommollCForeroGMathewsMVilazodone in patients with generalized anxiety disorder: a double-blind, randomized, placebo-controlled, flexible-dose studyInt Clin Psychopharmacol201530629730626291335
   PubMed Web of Science ®Google Scholar
• DurgamSGommollCForeroGEfficacy and safety of vilazodone in patients with generalized anxiety disorder: a randomized, double-blind, placebo-controlled, flexible-dose trialJ Clin Psychiatry201677121687169427232052
   PubMed Web of Science ®Google Scholar
• RobinsonDSKajdaszDKGallipoliSA 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorderJ Clin Psychopharmacol201131564364621869687
   PubMed Web of Science ®Google Scholar
• FergusonJMSSRI Antidepressant medications: adverse effects and tolerabilityPrim Care Companion J Clin Psychiatry200131222715014625
   PubMedGoogle Scholar
• ClaytonAHKennedySHEdwardsJBThe effect of vilazodone on sexual function during the treatment of major depressive disorderJ Sex Med201310102465247623216998
   PubMed Web of Science ®Google Scholar
• ClaytonAHDurgamSLiDEffects of vilazodone on sexual functioning in healthy adults: results from a randomized, double-blind, placebo-controlled, and active-controlled studyInt Clin Psychopharmacol2017321273527643885
   PubMed Web of Science ®Google Scholar
• 2015 Florida Best Practice Psychotherapeutic Medication Guidelines for AdultsThe University of South Florida, Florida Medicaid Drug Therapy Management Program sponsored by the Florida Agency for Health Care Administration Available from: www.medicaidmental-health.orgAccessed June 1, 2017
   Google Scholar